Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 Asthma-Reference-Cited by-同舟云学术

Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 Asthma

Published:2024-04 Issue:4 Volume:21 Page:675-679
ISSN:2329-6933
Container-title:Annals of the American Thoracic Society
language:en
Short-container-title:Annals ATS

Author:

Papi Alberto¹^ORCID,Castro Mario²^ORCID,Busse William W.³^ORCID,Langton David⁴,Korn Stephanie⁵⁶,Xia Changming⁷,Soler Xavier⁷,Pandit-Abid Nami⁸^ORCID,Radwan Amr⁷^ORCID,Jacob-Nara Juby A.⁸^ORCID,Rowe Paul J.⁸,Deniz Yamo⁷

Affiliation:

1. University of Ferrara, S. Anna University HospitalFerrara, Italy

2. University of Kansas School of MedicineKansas City, Kansas

3. University of Wisconsin School of Medicine and Public HealthMadison, Wisconsin

4. Monash UniversityClayton, Victoria, Australia

5. IKF Pneumologie MainzMainz, Germany

6. Thoraxklinik HeidelbergHeidelberg, Germany

7. Regeneron Pharmaceuticals Inc.Tarrytown, New York

8. SanofiBridgewater, New Jersey

Funder

Regeneron Pharmaceuticals Inc.

Sanofi

Publisher

American Thoracic Society

Link

https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.202306-544RL

Reference22 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

2. Severe exacerbations predict excess lung function decline in asthma

3. Lung function decline in asthma

4. Severe Exacerbations and Decline in Lung Function in Asthma

5. Asthma exacerbations and lung function in patients with severe or difficult-to-treat asthma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term safety, durability of response, cessation and switching of biologics;Current Opinion in Pulmonary Medicine;2024-03-01